How Effective Is Sivextro for Bacterial Infections?
Sivextro (tedizolid phosphate) is an FDA-approved antibiotic that works against acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including MRSA. Clinical trials showed it clears infections comparably to linezolid: in the ESTABLISH-1 trial, 97.6% of tedizolid patients had early clinical response (48-72 hours post-treatment) versus 93.2% on linezolid; ESTABLISH-2 showed 92.4% versus 91.5%.[1][2]
It shortens treatment to 6 days (versus 10 for linezolid) with similar cure rates around 90% at end-of-therapy.[1]
What Infections Does Sivextro Target?
Approved only for ABSSSI in adults, including cellulitis, wound infections, and major abscesses. It inhibits bacterial protein synthesis by binding the 50S ribosomal subunit, effective against staphylococci (including MRSA), streptococci, and enterococci. Not for pneumonia, bloodstream infections, or Gram-negative bacteria.[2][3]
Does It Work Against MRSA?
Yes, in trials, 88-92% success against MRSA ABSSSI, matching linezolid. MIC90 values show potency against resistant strains (≤0.5 mcg/mL for most MRSA).[1][4] Real-world data supports use in outpatient settings for MRSA skin infections.
How Does Sivextro Compare to Linezolid or Daptomycin?
| Drug | Daily Dose | Treatment Days | MRSA Cure Rate (Trials) | Key Edge |
|------|------------|---------------|-------------------------|----------|
| Sivextro | 200 mg oral/IV | 6 | 92% | Shorter course, less myelosuppression |
| Linezolid | 600 mg oral/IV | 10 | 90% | Broader label (includes pneumonia) |
| Daptomycin | 4 mg/kg IV | 7-14 | 90-95% | Stronger for deep infections |
Sivextro has lower toxicity risk (e.g., 2-3% thrombocytopenia vs. 10% for linezolid).[1][5] No head-to-head with vancomycin, but indirect data favors oxazolidinones for skin infections.
When Does Sivextro Fail or Underperform?
Failure rates ~5-10% in trials, often due to resistant isolates (e.g., tedizolid MIC >2 mcg/mL), non-susceptible pathogens, or poor adherence. Not for vancomycin-resistant Enterococcus faecalis. Avoid in bacteremia or osteomyelitis without specialist input.[2][3]
Patients with severe renal/hepatic impairment need dose adjustments; efficacy drops if compliance lapses due to once-daily dosing.
Who Makes Sivextro and What's the Patent Status?
Merck & Co. manufactures it. U.S. Patent 8,475,825 (core composition) expires December 2027; pediatric exclusivity adds 6 months to 2028. No generics approved yet; challenges ongoing via ANDA Paragraph IV filings.[6]
[1] FDA Label for Sivextro
[2] Prokesch et al., Clin Infect Dis 2014
[3] Moran et al., Clin Infect Dis 2014
[4] FLA0001, J Antimicrob Chemother 2012
[5] Lodise et al., Diagn Microbiol Infect Dis 2016
[6] DrugPatentWatch.com - Sivextro Patents